Palavras-chave
Como Citar
Resumo
Pancreatic cancer is one of the cancers with the highest mortality rate, largely due to the aggressiveness of the tumor cells and the lack of obvious symptoms at the beginning of the disease. Based on this, the present review aims to analyze the effectiveness of using oncolytic viruses in the treatment of pancreatic neoplasms. To this end, using the PCC research strategy, an acronym for eligibility criteria that means Population, Concept, and Context, the scientific databases PubMed/MEDLINE, LILACS, EMBASE, and ScienceDirect were used. After applying the processes of inclusion, exclusion, selection, data extraction, and assessment of the Level of Evidence, the results were six articles analyzed and used for the scoping review. At the end of the analysis of these articles, two of them detected the DNA of the viruses in the patients' blood, two presented grade I-II adverse events, and two used the same virus. Thus, five of the six articles analyzed demonstrated positive results, with the sixth being considered inconclusive. Therefore, it can be concluded that the treatment of pancreatic neoplasms with the use of oncolytic viruses, depending on the virus and the doses used, presents positive prospects for regression or interruption of the worsening of the disease, proving to be a source of hope for the future.
Referências
Zhao Z, Liu W. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technol Cancer Res Amp Treat [Internet]. Jan 1, 2020 [cited Feb 18, 2024];19:153303382096211. Available from: https://doi.org/10.1177/1533033820962117
Grant TJ, Hua K, Singh A. Molecular Pathogenesis of Pancreatic Cancer. Prog Mol Biol Transl Sci [Internet]. 2016 [cited Feb 18, 2024];144:241-275. doi: 10.1016/bs.pmbts.2016.09.008. Epub 2016 Oct 15. PMID: 27865459; PMCID: PMC6260831.
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Amp Hepatol [Internet]. May 17, 2021 [cited Feb 18, 2024];18(7):493- 502. Available from: https://doi.org/10.1038/s41575-021-00457-x
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA [Internet]. Feb 4, 2021 [cited Feb 18, 2024];71(3):209-49. Available from: https://doi.org/10.3322/caac.21660
Capasso M, Franceschi M, Rodriguez-Castro KI, Crafa P, Cambiè G, Miraglia C, Barchi A, Nouvenne A, Leandro G, Meschi T, De' Angelis GL, Di Mario F. Epidemiology and risk factors of pancreatic cancer. Acta Biomed [Internet]. 2018 Dec 17 [cited Feb 18, 2024]] . 89(9-S):141-146. Available from: https://pubmed.ncbi.nlm.nih.gov/30561407/
Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Investig Surg [Internet]. Oct 3, 2022 [cited Feb 18, 2024]:1-11. Available from: https://doi.org/10.1080/08941939.2022.2129884
Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell [Internet]. Apr 2023 [cited Feb 18, 2024];186(8):1729-54. Available from: https://doi.org/10.1016/j.cell.2023.02.014
Lermite E, Sommacale D, Piardi T, Arnaud JP, Sauvanet A, Dejong CH, Pessaux P. Complications after pancreatic resection: diagnosis, prevention and management. Clin Res Hepatol Gastroenterol [Internet]. Jun 2013 [cited Feb 18, 2024];37(3):230-9. Available from: https://doi.org/10.1016/j.clinre.2013.01.003
Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Medicale [Internet]. Mar 2019 [cited Feb 18, 2024];48(3):e159-e174. Available from: https://doi.org/10.1016/j.lpm.2019.02.025
Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic viruses in cancer therapy. Hum Vaccines Amp Immunother [Internet]. 20 Feb 2020 [cited 18 Feb 2024];16(10):2389-402. Available from: https://doi.org/10.1080/21645515.2020.1723363
Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci [Internet]. Sep 9, 2016 [cited Feb 18, 2024];107(10):1373-9. Available from: https://doi.org/10.1111/cas.13027
Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol [Internet]. Feb 2005 [cited Feb 3, 2024];8(1):19-32. Available from: https://doi.org/10.1080/1364557032000119616
Thomas A, Lubarsky S, Durning SJ, Young ME. Knowledge syntheses in medical education. Acad Med [Internet]. Feb 2017 [cited Feb 3, 2024];92(2):161-6. Available from: https://doi.org/10.1097/acm.0000000000001452
Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MD, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA extension for scoping reviews (prisma-scr): checklist and explanation. Ann Intern Med [Internet]. Sep 4, 2018 [cited Feb 3, 2024];169(7):467. Available from: https://doi.org/10.7326/m18-0850
Oliveira Araújo WC. Health information retrieval. Converg Em Cienc Informacao [Internet]. Jul 10, 2020 [cited Feb 3, 2024];3(2):100-34. Available at: https://doi.org/10.33467/conci.v3i2.13447
Galvão TF, Pereira MG. Assessing the quality of evidence from systematic reviews. Epidemiologia Serv Saude [Internet]. Mar 2015 [cited Feb 3, 2024];24(1):775-8. Disponível em: https://doi.org/10.5123/s1679-49742015000100019
Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Mol Ther Oncolytics [Internet]. Mar 2019 [cited 2024 Mar 1];12:56-67. Available from: https://doi.org/10.1016/j.omto.2018.12.005
Costanzi-Strauss E, Strauss BE. Perspectives on gene therapy. Rev Medicina [Internet]. 22 Dec 2015 [cited 1 Mar 2024];94(4):211. Disponível em: https://doi.org/10.11606/issn.1679-9836.v94i4p211-222
Barton KN, Siddiqui F, Pompa R, Freytag SO, Khan G, Dobrosotskaya I, Ajlouni M, Zhang Y, Cheng J, Movsas B, Kwon D. Phase I Trial Of Oncolytic Adenovirus-Mediated Cytotoxic And Interleukin-12 Gene Therapy For The Treatment Of Metastatic Pancreatic Cancer. Mol Ther Oncolytics [Internet]. Dec 2020 [cited 1 Mar 2024]. Available from: https://doi.org/10.1016/j.omto.2020.11.006
Mahalingam D, Wilkinson GA, Eng KH, Fields P, Raber P, Moseley JL, Cheetham K, Coffey M, Nuovo G, Kalinski P, Zhang B, Arora SP, Fountzilas C. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Clin Cancer Res [Internet]. Nov 6, 2019 [cited March 1, 2024];26(1):71-81. Available from: https://doi.org/10.1158/1078-0432.ccr-19-2078
Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther [Internet]. Jun 2016 [cited 1 Mar 2024];24(6):1150-8. Available from: https://doi.org/10.1038/mt.2016.66
Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, Álvarez R, Mato-Berciano A, Gimenez-Alejandre M, Morgado S, Rodríguez-García A, Maliandi MV, Riesco MC, Moreno R, Ginestà MM, Perez-Carreras M, Gornals JB, Prados S, Perea S, Capella G, Alemany R, Salazar R, Blasi E, Blasco C, Cascallo M, Hidalgo M. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J Immunother Cancer [Internet]. Nov 2021 [cited 1 Mar 2024];9(11):e003254. Available from: https://doi.org/10.1136/jitc-2021-003254
Musher BL, Smaglo BG, Abidi W, Othman M, Patel K, Jing J, Stanietzky N, Lu J(, Brisco A, Wenthe J, Brenner B, Eriksson E, Leen AM, Hilsenbeck SG, Ullenhag GJ, Rowinsky EK, Grilley B, Loskog AS.A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report. J Clin Oncol [Internet]. Feb 1, 2020 [cited March 1, 2024];38(4_suppl):716. Available at: https://doi.org/10.1200/jco.2020.38.4_suppl.716
Kandi V, Vadakedath S. Clinical Trials and Clinical Research: A Comprehensive Review. Cureus [Internet]. Feb 16, 2023 [cited March 10, 2024]. Available from: https://doi.org/10.7759/cureus.35077
Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM. Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma. Mol Ther [Internet]. Sep 2009 [cited 10 Mar 2024];17(9):1651-7. Available from: https://doi.org/10.1038/mt.2009.126
Goel S, Ocean AJ, Parakrama RY, Ghalib MH, Chaudhary I, Shah U, Viswanathan S, Kharkwal H, Coffey M, Maitra R. Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. Mol Cancer Ther [Internet]. Mar 10, 2020 [cited Mar 10, 2024];19(5):1148-56. Disponível em: https://doi.org/10.1158/1535-7163.mct-19-1117.
Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. Lung Cancer [Internet]. Jun 2018 [cited 10 Mar 2024];120:142-8. Available from: https://doi.org/10.1016/j.lungcan.2018.03.005.
Eriksson E, Milenova I, Wenthe J, Ståhle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus. Clin Cancer Res [Internet]. 23 May 2017 [cited 10 Mar 2024];23(19):5846-57. Available at: https://doi.org/10.1158/1078-0432.ccr-17-0285
Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martín M, Álvarez R, Macarulla T, Riesco-Martinez MC, Verdaguer H, Guillén-Ponce C, Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi MV, Torres-Manjon S, Costa M, del Pozo N, Martínez de Villarreal J, Real FX, Vidal N, Capella G, Alemany R, Blasi E, Blasco C, Cascalló M, Salazar R. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J Immunother Cancer [Internet]. Mar 2022 [cited March 10, 2024];10(3):e003255. Available from: https://doi.org/10.1136/jitc-2021-003255
Freytag SO, Barton KN, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther [Internet]. Jul 11, 2013 [cited March 10, 2024];20(12):1131-9. Available from: https://doi.org/10.1038/gt.2013.40
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Maria Eduarda Duarte Maroja, Maria Eduarda Gomes de Almeida, Manuela Souto Garcia Lavalle, Antônio Carlos de Melo Tompson, Amanda Cirne Schwartz, Kalyel Gomes Muniz, Mateus Henrique Dornelles Baz, Paulo Gabriel Soares da Silva, Hugo Rafael de Souza e Silva